BioMedNewsBreaks

TuesdayMay 13, 2025 9:00 am

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics to Acquire Kadima Neuropsychiatry Institute

NRx Pharmaceuticals (NASDAQ: NRXP) announced that its wholly owned subsidiary, HOPE Therapeutics(TM), has signed a definitive agreement to acquire the Kadima Neuropsychiatry Institute. Kadima, a leading California clinic for interventional psychiatry, offers treatments such as ketamine, Spravato, transcranial magnetic stimulation (TMS), and medication management for CNS disorders including suicidal depression and PTSD. The clinic is profitable and expected to serve as the clinical model for future HOPE clinics. Dr. David Feifel, Kadima’s founder and a nationally recognized leader in interventional psychiatry, will join HOPE as its first Chief Medical Innovation Officer following the closing of the acquisition, which remains subject…

Continue Reading

MondayMay 12, 2025 11:07 am

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Q1 2025 Results on May 15 

NRx Pharmaceuticals (NASDAQ: NRXP) announced it will release its first quarter 2025 financial results after market close on Thursday, May 15, 2025. The company will host a conference call at 4:30 p.m. ET the same day to discuss the results and provide a corporate update.  To view the full press release, visit https://ibn.fm/xT1TQ  About NRx Pharmaceuticals, Inc.  NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant…

Continue Reading

FridayMay 09, 2025 2:54 pm

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Eyes Game-Changing Approach to Cancer Treatment

Calidi Biotherapeutics (NYSE American: CLDI) recently announced promising preclinical results for its innovative RTNova platform, which has successfully delivered transient gene-therapy payloads to targeted tumors. In addition, Calidi’s virotherapy demonstrated efficacy in killing more than 60 different tumor cell lines, showcasing the platform’s potential to revolutionize cancer treatment by enabling both tumor destruction and robust immune activation. “Targeting tumors with a systemic virotherapy with a multimodal mechanism of action, which includes direct killing of the tumors and robust activation of antitumor immune responses, may revolutionize the way we approach cancer treatments,” said a Calidi spokesman. “We are excited to have shown…

Continue Reading

ThursdayMay 08, 2025 3:37 pm

BioMedNewsBreaks — Adageis’ AI-Powered Platform Empowers Smarter Billing, Better Care

Adageis, a healthcare technology company, is transforming how providers manage insurance payments with its AI-driven software platform, designed to enhance transparency, ensure reimbursement, and support the shift to value-based care. By offering real-time insights into expected payments, identifying reimbursement gaps, and evaluating performance, Adageis empowers clinics—especially smaller or new practices—to optimize revenue, negotiate better insurance contracts, and make informed financial decisions. The platform helps providers navigate complex insurance arrangements while improving profitability, quality, and a focus on patient care. With growing interest in the healthcare technology sector, Adageis stands out as a promising investment opportunity. To view the full article,…

Continue Reading

ThursdayMay 08, 2025 11:26 am

BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports $4.8 Million Net Gain in 2024, Driven by Loan-to-Equity Conversion 

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharma company focused on inflammation and immunology treatments and CDMO services, reported a $4.8 million net gain for 2024, reversing a $6.5 million loss in 2023. The improvement was largely due to $14.8 million in financial income from a loan-to-equity conversion. The company posted $658,000 in revenue—its first ever—from its CDMO unit. R&D expenses remained steady at $5.6 million, while G&A costs dropped to $2.6 million. Cash and equivalents totaled $1.9 million at year-end.  To view the full press release, visit https://ibn.fm/zHuHv  About Scinai Immunotherapeutics Ltd.  Scinai is a biopharmaceutical company with two complementary business units. One…

Continue Reading

WednesdayMay 07, 2025 12:28 pm

BioMedNewsBreaks — Soligenix Inc. (SNGX) CEO Highlights Pipeline and Strategy in Latest BioMedWire Podcast Episode

Soligenix (SNGX) Chairman and CEO Dr. Christopher Schaber joined IBN’s BioMedWire Podcast to discuss the company’s two-pronged business model, robust late-stage pipeline, and ongoing clinical trials. Schaber emphasized Soligenix’s focus on rare disease therapeutics and its Public Health Solutions segment, which has received over $60 million in non-dilutive U.S. government funding. He also outlined near-term milestones, including a confirmatory Phase 3 trial, active partnership discussions, and continued pursuit of strategic opportunities.  To view the full press release, visit https://ibn.fm/cdTsU  About Soligenix, Inc.  Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there…

Continue Reading

TuesdayMay 06, 2025 11:44 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Adds Two U.S. Patents to Bolster Cardiac Monitoring IP Portfolio 

HeartBeam (NASDAQ: BEAT), a medical technology company advancing personalized cardiac care, announced the issuance of two new U.S. patents that strengthen its intellectual property position. The first patent covers the company’s credit card-sized, cable-free 3D ECG device, which enables real-time cardiac monitoring and symptom capture. The second patent protects its rhythm analysis algorithm, which identifies arrhythmias using continuous signal input and prompts users to collect 3D ECG data when anomalies are detected. These additions expand HeartBeam’s patent count to 20 issued and 34 others pending or allowed, reinforcing its platform ahead of future product extensions and FDA review of its…

Continue Reading

TuesdayMay 06, 2025 10:20 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) to Announce Q1 2025 Results on May 15, Hosts Investor Call at 8:30 a.m.

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, will release its financial results for the quarter ended March 31, 2025, before market open on May 15. Management will host a conference call at 8:30 a.m. EDT the same day, led by Executive Chairman and CEO Charles M. Fernandez, CFO Cecile Munnik, and President and CEO of Global Operations David Phipps. To view the full press release, visit: https://ibn.fm/ttpQg About NextPlat Corp NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets including technology and healthcare. Through acquisitions, joint ventures and collaborations, the company intends…

Continue Reading

MondayMay 05, 2025 9:30 am

BioMedNewsBreaks — VERAXA Biotech AG Launches Bispecific ADC Discovery Alliance with OmniAb (NASDAQ: OABI) 

VERAXA Biotech AG, a cancer therapy innovator, and proposed de-SPAC target of Voyager Acquisition Corp. (NASDAQ: VACH), announced a co-discovery alliance with OmniAb Inc. (NASDAQ: OABI) to jointly develop a novel bispecific antibody drug conjugate (“bsADC”) program targeting solid tumors. The collaboration combines OmniAb’s transgenic antibody discovery platform with VERAXA’s proprietary ADC linker and conjugation technology to create next-generation cancer therapeutics. Under the agreement, VERAXA will lead preclinical development using two selected cancer targets, while both companies will co-own the program and share future revenues from its advancement, licensing and commercialization. This marks VERAXA’s second major strategic initiative in six…

Continue Reading

MondayMay 05, 2025 9:24 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Appoints CEO Robert Eno to Board of Directors 

HeartBeam (NASDAQ: BEAT) a medical technology company advancing personalized cardiac care, has appointed Chief Executive Officer Robert Eno to its Board of Directors, expanding the board from eight to nine members. Eno, who joined the company as president in January 2023 and became CEO in October 2024, brings over 30 years of medtech leadership experience, including launching disruptive technologies. His appointment comes as the company prepares for the commercial launch of its 3D ECG technology, pending FDA clearance of its 12-lead ECG synthesis software.  To view the full press release, visit https://ibn.fm/7SiVW  About HeartBeam Inc.  HeartBeam is a medical technology…

Continue Reading